CLX - Solid Quarter, Top Line Flattered by Items

Clorox (CLX) reported Q2 ’13 EPS this morning, a solid result of $0.90 ($0.03 gain in the quarter included in reported results) versus consensus of $0.81.  We didn’t see much to do into the quarter, as our estimate was ahead of consensus.  Our bias is to look to be short the name, as we view its multiple (18.6x ’13) as disproportionate to its long-term growth rate (3-5% top line).  However, valuation isn’t a sufficient catalyst for us, so we will remain on the sidelines waiting for a clearer path to an EPS or top line miss is apparent.  We may not have to wait long, depending upon how consensus shakes out for Q3.



The clear standout in the quarter was the company’s 7.1% constant currency organic top line growth (against a 4.1% in the year ago quarter).  However, it appears that the number was flattered by:

  1. Early shipments (in Household, specifically charcoal)
  2. Robust flu season (disinfecting wipes – strong retailer buy-in, takeaway was very good as well, unclear what inventory status is) - not sustainable
  3. New products (bleach, lip care and dressings)

We should point out that the only segment that didn't have some sort of volume "noise" associated with it was International, which saw volumes decline 3 percent.



The upcoming quarter represents the most difficult year over year top line comparison (+5.9%) and will likely suffer from what flattered this quarter’s results.  We will wait and see where consensus shakes out.

 

-Rob

 

Robert  Campagnino

Managing Director

HEDGEYE RISK MANAGEMENT, LLC

E:

P:

 

Matthew Hedrick

Senior Analyst




Cartoon of the Day: Acrophobia

"Most people who are making a ton of money right now are focused on growth companies seeing accelerations," Hedgeye CEO Keith McCullough wrote in today's Early Look. "That’s what happens in Quad 1."

read more

People's Bank of China Spins China’s Bad-Loan Data

PBoC Deputy Governor Yi says China's non-performing loan problem has “pretty much stabilized." "Yi is spinning. China’s bad-debt problem remains serious," write Benn Steil and Emma Smith, Council on Foreign Relations.

read more

UnderArmour: 'I Am Much More Bearish Than I Was 3 Hours Ago'

“The consumer has a short memory.” Yes, Plank actually said this," writes Hedgeye Retail analyst Brian McGough. "Last time I heard such arrogance was Ron Johnson."

read more

Buffalo Wild Wings: Complacency & Lack of Leadership (by Howard Penney)

"Buffalo Wild Wings has been plagued by complacency and a continued lack of adequate leadership," writes Hedgeye Restaurants analyst Howard Penney.

read more

Todd Jordan on Las Vegas Sands Earnings

"The quarter actually beat lowered expectations. Overall, the mass segment performed well although base mass lagging is a concern," writes Hedgeye Gaming, Lodging & Leisure analyst Todd Jordan on Las Vegas Sands.

read more

An Update on Defense Spending by Lt. Gen Emo Gardner

"Congress' FY17 omnibus appropriation will fully fund the Pentagon's original budget request plus $15B of its $30B supplemental request," writes Hedgeye Potomac Defense Policy analyst Lt. Gen Emerson "Emo" Gardner USMC Ret.

read more

Got Process? Zero Hedge Sells Fear, Not Truth

Fear sells. Always has. Look no further than Zero Hedge.

read more

REPLAY: Review of $EXAS Earnings Call (A Hedgeye Best Idea Long)

Our Healthcare Team made a monster call to be long EXAS - hear their updated thoughts.

read more

Capital Brief: 5 Things to Watch Right Now In Washington

Here's a quick look at some key issues investors should keep an eye on from Hedgeye's JT Taylor and our team of Washington Policy analysts in D.C.

read more

Premium insight

[UNLOCKED] Today's Daily Trading Ranges

“If I could only have one thing of the many things we have it would be my daily ranges." Hedgeye CEO Keith McCullough said recently.

read more

We'll Say It Again: Leave Your Politics Out of Your Portfolio

If your politics dictates your portfolio positioning, the Democrats and #NeverTrump crowd out there have had a hell of a week.

read more